Xenetic Biosciences, Inc. (NASDAQ: XBIO), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies for difficult-to-treat cancers, has released its financial results for the first quarter ended March 31, 2025. The company reported a net loss of approximately $0.9 million for the quarter. Revenue increased by approximately $0.1 million, or 16.1%, reaching approximately $0.6 million compared to approximately $0.5 million in the same period in 2024. Operating costs and expenses decreased by approximately $244,000, or 13.7%, to about $1.5 million from approximately $1.8 million in the comparable quarter in 2024. This decrease was primarily attributed to reduced personnel costs and share-based expenses following the departure of the company's former Chief Executive Officer and Chief Scientific Officer in the second quarter of 2024. Xenetic concluded the quarter with approximately $5.2 million in cash to support its operations. The company continues to focus on exploratory investigator-initiated clinical studies in collaboration with institutional partners. Significant progress has been made in the development of the DNase I program, with efforts moving towards an Investigational New Drug $(IND.AU)$ application and a first-in-human study for the treatment of pancreatic carcinoma. Additionally, Xenetic's collaboration with PeriNess Ltd. has led to a Clinical Study Agreement to advance the DNase platform for treating relapsed/refractory osteosarcoma and Ewing sarcoma. The company remains committed to pursuing strategic collaborations to advance its technology and development programs efficiently.